RhumbLine Advisers’s Abiomed Inc ABMD Stock Holding History

RhumbLine Advisers’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-83,549	Closed	-$20.5M	–	3058
2022 Q3	$20.5M	Buy	83,549 +1,268	+2%	+$342K	0.03%	513
2022 Q2	$20.4M	Buy	82,281 +3,600	+5%	+$971K	0.03%	523
2022 Q1	$26.1M	Sell	78,681 -3,927	-5%	-$1.21M	0.03%	458
2021 Q4	$29.7M	Sell	82,608 -3,247	-4%	-$1.1M	0.04%	443
2021 Q3	$27.9M	Buy	85,855 +1,443	+2%	+$489K	0.04%	429
2021 Q2	$26.3M	Sell	84,412 -997	-1%	-$306K	0.03%	467
2021 Q1	$27.2M	Sell	85,409 -2,527	-3%	-$809K	0.04%	452
2020 Q4	$28.5M	Buy	87,936 +816	+0.9%	+$226K	0.04%	416
2020 Q3	$24.1M	Sell	87,120 -4,057	-4%	-$1.17M	0.04%	414
2020 Q2	$22M	Sell	91,177 -3,829	-4%	-$769K	0.04%	418
2020 Q1	$13.8M	Buy	95,006 +2,982	+3%	+$495K	0.03%	525
2019 Q4	$15.7M	Buy	92,024 +5,572	+6%	+$1.03M	0.03%	596
2019 Q3	$15.4M	Buy	86,452 +2,698	+3%	+$583K	0.03%	562
2019 Q2	$21.8M	Sell	83,754 -4,503	-5%	-$1.19M	0.04%	420
2019 Q1	$25.2M	Sell	88,257 -2,763	-3%	-$918K	0.05%	351
2018 Q4	$29.6M	Buy	91,020 +520	+0.6%	+$181K	0.06%	275
2018 Q3	$40.7M	Buy	90,500 +1,120	+1%	+$442K	0.08%	245
2018 Q2	$36.6M	Sell	89,380 -8,197	-8%	-$2.97M	0.07%	266
2018 Q1	$28.4M	Sell	97,577 -5,476	-5%	-$1.39M	0.06%	329
2017 Q4	$19.3M	Sell	103,053 -1,263	-1%	-$236K	0.04%	454
2017 Q3	$17.6M	Buy	104,316 +11,571	+12%	+$1.75M	0.04%	464
2017 Q2	$13.3M	Buy	92,745 +675	+0.7%	+$90.7K	0.03%	536
2017 Q1	$11.5M	Buy	92,070 +2,706	+3%	+$314K	0.03%	589
2016 Q4	$10.1M	Buy	89,364 +3,913	+5%	+$453K	0.03%	611
2016 Q3	$11M	Buy	85,451 +3,931	+5%	+$471K	0.03%	537
2016 Q2	$8.91M	Sell	81,520 -3,705	-4%	-$369K	0.03%	579
2016 Q1	$8.08M	Buy	85,225 +23,346	+38%	+$1.97M	0.03%	622
2015 Q4	$5.59M	Buy	61,879 +5,180	+9%	+$440K	0.02%	768
2015 Q3	$5.26M	Buy	56,699 +2,396	+4%	+$211K	0.02%	781
2015 Q2	$3.57M	Sell	54,303 -770	-1%	-$51.2K	0.01%	1046
2015 Q1	$3.94M	Buy	55,073 +5,930	+12%	+$322K	0.01%	967
2014 Q4	$1.87M	Sell	49,143 -521	-1%	-$16.4K	0.01%	1400
2014 Q3	$1.23M	Sell	49,664 -5	-0%	-$127	﹤0.01%	1622
2014 Q2	$1.25M	Sell	49,669 -527	-1%	-$12.3K	﹤0.01%	1682
2014 Q1	$1.31M	Sell	50,196 -2,400	-5%	-$66.4K	﹤0.01%	1632
2013 Q4	$1.41M	Sell	52,596 -390	-0.7%	-$9.64K	﹤0.01%	1582
2013 Q3	$1.01M	Sell	52,986 -763	-1%	-$17.4K	﹤0.01%	1778
2013 Q2	$1.16M	Buy	+53,749	New	+$1.08M	﹤0.01%	1656

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

RhumbLine Advisers's ABMD Position: Q4 2022 in Review

RhumbLine Advisers sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 83,549 shares — an estimated $20.5M sold.

RhumbLine Advisers first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $40.7M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

RhumbLine Advisers reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
RhumbLine Advisers sold 83,549 Abiomed Inc shares in Q4 2022, an estimated $20.5M.
RhumbLine Advisers first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
RhumbLine Advisers's Abiomed Inc position peaked at $40.7M in Q3 2018.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on RhumbLine Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.